Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/05/2020 08/06/2020 08/07/2020 08/10/2020 08/11/2020 Date
51.98(c) 50.46(c) 50.45(c) 51.74(c) 52.97(c) Last
2 711 519 1 804 551 937 293 1 061 924 1 126 274 Volume
-5.70% -2.92% -0.02% +2.56% +2.38% Change
More quotes
Financials (USD)
Sales 2020 5 161 M - -
Net income 2020 246 M - -
Net Debt 2020 2 721 M - -
P/E ratio 2020 24,8x
Yield 2020 1,69%
Sales 2021 5 265 M - -
Net income 2021 310 M - -
Net Debt 2021 2 321 M - -
P/E ratio 2021 20,4x
Yield 2021 1,83%
Capitalization 7 229 M 7 229 M -
EV / Sales 2020 1,93x
EV / Sales 2021 1,81x
Nbr of Employees 11 200
Free-Float 99,4%
More Financials
Company
Perrigo Company plc develops, produces, and sells therapy and care products. Sales break down by product family as follows: - consumable care products (80%). The group also offers medical diagnostic products. Net sales break down by geographical area between the United States/Canada/Mexico (64.3%), Europe and Australia (35,7%); - generic prescription drugs (20%). At the end of 2019, the group has 93 production... 
Sector
Pharmaceuticals
Calendar
08/27Ex-dividend day for
More about the company
Surperformance© ratings of Perrigo Company plc
Trading Rating : - Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY PLC
08/10PERRIGO : Global Legal Insights Corporate Tax 2020
AQ
08/05PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/05PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
08/05PERRIGO : 2Q Earnings Snapshot
AQ
06/24PERRIGO CO PLC : Change in Directors or Principal Officers (form 8-K)
AQ
06/24PERRIGO : Furthers Its Consumer-Focused Transformation by Divesting Its U.K. Gen..
AQ
06/19PERRIGO CO PLC : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
06/19PERRIGO : Partners With Kazmira LLC to Enter CBD Market through a Two-Phased, Sc..
AQ
05/28PERRIGO COMPANY PLC : Ex-dividend day for
FA
05/06PERRIGO COMPANY PLC : Proxy Statments
CO
05/06PERRIGO COMPANY PLC : Report
CO
05/05PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
04/30PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
04/30PERRIGO : 1Q Earnings Snapshot
AQ
04/30PERRIGO COMPANY PLC : 1st quarter results
CO
More news
News in other languages on PERRIGO COMPANY PLC
08/10PERRIGO : Global Legal Insights Corporate Tax 2020
08/05PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
08/05PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
08/05PERRIGO : 2Q Earnings Snapshot
06/24PERRIGO CO PLC : Change in Directors or Principal Officers (form 8-K)
More news
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 55,56 $
Last Close Price 52,97 $
Spread / Highest target 20,8%
Spread / Average Target 4,88%
Spread / Lowest Target -24,5%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Raymond P. Silcock Chief Financial & Accounting Officer
Thomas Farrington Chief Information Officer & Executive VP
Grainne Quinn Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC2.54%7 061
JOHNSON & JOHNSON1.87%389 737
ROCHE HOLDING AG-0.11%293 027
PFIZER, INC.-2.02%213 329
MERCK & CO., INC.-11.04%204 641
NOVARTIS AG-17.86%181 730